Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

China’s National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptionsNew, one-time $199 ...

The Food and Drug Administration (FDA) approved Wegovy (semaglutide) in 2021 for chronic (long-term) weight management.In 2024, the FDA approved the drug for an additional use: to reduce the risk ...

With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptionsNew, one-time $199 ...